RxDoctor Payments Data

Jonathan Carlson, MD

Interventional Pain Medicine · Kailua, HINPI 1538206644

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 51.6% of the total. Reporting peaked in 2019 at $72,229 and has fallen 97.0% since, to $2,143 in 2025.

$128,778in general payments, 2019–2025

Across 490 payments — averaging $262.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$66K
  • Vertiflex, Inc.$40K
  • Boston Scientific$11K
  • Biotronik NRO, Inc.$4K
  • Medtronic$1K
  • Painteq LLC$1K
  • plus $5K from 23 others
$24,387in research payments, 2019–2025

Across 18 payments — averaging $1354.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mesoblast, Inc.$16K
  • Abbott$7K
  • Nevro Corp.$1K
  • Saluda Medical Americas, Inc.$43

What the payments were for

  • Consulting fees$51,88040%
  • Speaking & faculty fees$39,65731%
  • Travel & lodging$15,21712%
  • Food & beverage$22,02517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$159,698
Medicare patients
138
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib72$2,467
Gabapentin110$2,184
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen88$1,592
Pregabalin66$1,056
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$914
Morphine Sulfate ErMorphine Sulfate45$819
Nabumetone35$763
Tizanidine Hcl36$738
Methocarbamol53$735
Oxycodone Hcl25$731
Tramadol Hcl63$668

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Kailua

Where these figures come from

Is this you, or does something look wrong? →